Rectal neuroendocrine tumor

Summary

Rectal neuroendocrine tumor (MONDO:0015068) is a cancer and 5 clinical trials. A subtype of digestive system neuroendocrine tumor, grade 1/2 — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Phenotypes (HPO): 25
• Clinical trials: 5

Clinical features

Signs & symptoms

Clinical features (HPO)

25 HPO clinical features (Orphanet curated; top 25 by frequency):

HPO ID	Term	Frequency
HP:0100570	Carcinoid tumor	Obligate (100%)
HP:0001824	Weight loss	Frequent (30-79%)
HP:0002019	Constipation	Frequent (30-79%)
HP:0002027	Abdominal pain	Frequent (30-79%)
HP:0002039	Anorexia	Frequent (30-79%)
HP:0002573	Hematochezia	Frequent (30-79%)
HP:0012702	Tenesmus	Frequent (30-79%)
HP:0025085	Bloody diarrhea	Frequent (30-79%)
HP:0030144	Hypoactive bowel sounds	Frequent (30-79%)
HP:0030446	Atypical pulmonary carcinoid tumor	Frequent (30-79%)
HP:0002240	Hepatomegaly	Occasional (5-29%)
HP:0002249	Melena	Occasional (5-29%)
HP:0002730	Chronic noninfectious lymphadenopathy	Occasional (5-29%)
HP:0002910	Elevated circulating hepatic transaminase concentration	Occasional (5-29%)
HP:4000007	Bronchoconstriction	Very rare (<1-4%)
HP:0001708	Right ventricular failure	Very rare (<1-4%)
HP:0001962	Palpitations	Very rare (<1-4%)
HP:0002615	Hypotension	Very rare (<1-4%)
HP:0003144	Increased serum serotonin	Very rare (<1-4%)
HP:0004385	Protracted diarrhea	Very rare (<1-4%)
HP:0005180	Tricuspid regurgitation	Very rare (<1-4%)
HP:0007380	Facial telangiectasia	Very rare (<1-4%)
HP:0012701	Bowel urgency	Very rare (<1-4%)
HP:0030145	Lack of bowel sounds	Very rare (<1-4%)
HP:0031566	Abnormal pulmonary valve cusp morphology	Very rare (<1-4%)

Identifiers

Disease identifiers

Field	Value
Canonical name	rectal neuroendocrine tumor
Mondo ID	MONDO:0015068
Orphanet	100081
NCIT	C135213
UMLS	C5554035
MedGen	1810164
GARD	0025058
Anatomy (UBERON)	UBERON:0001052
Is cancer (heuristic)	yes

Also known as: neuroendocrine tumor of rectum, well differentiated, low or intermediate grade · rectal well differentiated neuroendocrine neoplasm · rectal well-differentiated neuroendocrine neoplasm

Data availability: 1 cell line.

Disease family

This is a subtype of digestive system neuroendocrine tumor, grade 1/2. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system neuroendocrine neoplasm › digestive system neuroendocrine tumor, grade 1/2 › rectal neuroendocrine tumor

Related subtypes (9): small intestine neuroendocrine tumor, well differentiated, low or intermediate grade, gastrin-producing neuroendocrine tumor, esophageal neuroendocrine tumor, L-cell glucagon-like peptide-producing neuroendocrine tumor, gastric neuroendocrine tumor, well differentiated, low or intermediate grade, neuroendocrine tumor of the colon, well differentiated, low or intermediate grade tumor, gallbladder neuroendocrine tumor, grade 1/2, pancreatic neuroendocrine tumor, intestinal neuroendocrine tumor G1

Subtypes (2): neuroendocrine tumor of the anal canal, rectal neuroendocrine tumor G1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05429216	Not specified	NOT_YET_RECRUITING	Endoscopic Resection for Small Rectal Neuroendocrine Tumors
NCT06901856	Not specified	NOT_YET_RECRUITING	Endoscopic Resection for Small Rectal Neuroendocrine Tumors
NCT07373015	Not specified	NOT_YET_RECRUITING	Modified Double Snare Assisted EMR (mDS-EMR) VS ESD for Rectal Neuroendocrine Tumors Smaller Than 1cm
NCT07612748	Not specified	NOT_YET_RECRUITING	Two Different Endoscopic Treatments for Rectal Neuroendocrine Neoplasms
NCT03982264	Not specified	UNKNOWN	Endoscopic Treatment of Rectal Neuroendocrine Tumor(NET) Less Than 10mm